Abstract:B. longum has been reported to exert an alleviative effect on colitis, but the results also suggested significant differences among strains. Here in this study, we compared the effect of B. longum subsp. longum strains with different properties in EPS production on DSS-induced colitis. To investigate the alleviative effect of a ropy-exopolysaccharide (EPS) producing strain, Bifidobacterium longum subsp. longum YS108R, on experimental colitis, C57BL/6J mice (male, 6-8 weeks old) were randomly assigned to six groups (n = 8): normal control, DSS colitis and four DSS colitis groups orally administered with three B. longum subsp. longum strains (YS108R, C11A10B and HAN4-25) and B. animalis subsp. lactis BB12, respectively, in which YS108R produced ropy-EPS, C11A10B produced non-ropy-EPS, HAN4-25 did not produce EPS and BB12 was set as a positive control. Ropy-EPS producing strain YS108R could alleviate the symptoms and remit inflammation induced by DSS, in which YS108R could decrease the pro-inflammatory cytokine IL-6 and IL-17A levels after DSS challenge (from 102 ± 45.22 to 37.95 ± 20.33 pg mL-1 and from 22.14 ± 5.43 to 12.58 ± 2.74, p < 0.05), but another non-ropy-EPS producing strain C11A10B did not decrease the levels of these pro-inflammatory cytokines. Furthermore, YS108R could maintain the expression levels of genes related to the mucosal barrier, but strain HAN4-25, a non-EPS producer, was not able to maintain the expression levels of these genes after DSS challenge. Analysis of gut microbiota showed that DSS treatment significantly increased the relative abundance of Enterobacteriaceae and Peptostreptococcaceae (0.2623 ± 0.162 and 0.0512 ± 0.0361) and decreased the relative abundance of S24-7 (0.042 ± 0.0326); however, YS108R administration could decrease the relative abundance of Enterobacteriaceae and Peptostreptococcaceae to 0.0848 ± 0.0399 and 0.0032 ± 0.0047 and increase the relative abundance of S24-7 to 0.2625 ± 0.0566 (p < 0.05). The results showed that B. longum subsp. longum YS108R could alleviate DSS-induced colitis by modulating the inflammation related cytokines, maintenance of the normal mucosal barrier and reverting the change of microbiota.

The Ecological Regulating Effect of Exopolysaccharides Produced by Bifidobacterium on Intestinal Microecological Imbalance

Paenibacillus Exopolysaccharide Repairs GI Inflammation by Suppressing MAPK and NF-κB and Restoring Lipid Production in Caco-2 Cell Line

The Beneficial Effect Of Exopolysaccharides From Bifidobacterium Bifidum Wbin03 On Microbial Diversity In Mouse Intestine

Study on Immunoregulation Effect of Exopolysaccharide Produced by Bifidobacterium spp

A Ropy Exopolysaccharide-Producing Strain Bifidobacterium pseudocatenulatum Bi-OTA128 Alleviates Dextran Sulfate Sodium-Induced Colitis in Mice

Effect of a Ropy Exopolysaccharide-Producing Bifidobacterium animalis subsp. lactis Strain Orally Administered on DSS-Induced Colitis Mice Model

Exopolysaccharide from Lactobacillus rhamnosus ZFM231 alleviates DSS-induced colitis in mice by regulating gut microbiota.

Exopolysaccharides from Lactobacillus plantarum YW11 improve immune response and ameliorate inflammatory bowel disease symptoms

A Role of Exopolysaccharide Produced by Streptococcus thermophilus in the Intestinal Inflammation and Mucosal Barrier in Caco-2 Monolayer and Dextran Sulphate Sodium-Induced Experimental Murine Colitis

Immunomodulation of Exopolysaccharide Produced by Lacticaseibacillus Rhamnosus ZFM216 in Cyclophosphamide-Induced Immunosuppressed Mice by Modulating Gut Microbiota

Exopolysaccharides from Lactobacillus Plantarum NCU116 Facilitate Intestinal Homeostasis by Modulating Intestinal Epithelial Regeneration and Microbiota.

Study on the regulatory effects and mechanisms of action of bifidobacterial exopolysaccharides on anaphylaxes in mice

<i>Bifidobacterium breve</i> Alleviates DSS-Induced Colitis in Mice by Maintaining the Mucosal and Epithelial Barriers and Modulating Gut Microbes

Exopolysaccharides from Bacillus Amyloliquefaciens DMBA-K4 Ameliorate Dextran Sodium Sulfate-Induced Colitis Via Gut Microbiota Modulation

Exopolysaccharides of Bifidobacterium Longum Subsp. Infantis E4 on the Immune and Anti-Inflammatory Effects in Vitro

Structural Analysis and Mucosal Immune Regulation of Exopolysaccharide Fraction from Bifidobacterium Animalis RH

Bifidobacterium breve Alleviates DSS-Induced Colitis in Mice by Maintaining the Mucosal and Epithelial Barriers and Modulating Gut Microbes

A Ropy Exopolysaccharide Producing Strain Bifidobacterium Longum Subsp. Longum YS108R Alleviates DSS-induced Colitis by Maintenance of the Mucosal Barrier and Gut Microbiota Modulation.

Gut microbiota modulation and anti-inflammatory properties of mixed lactobacilli in dextran sodium sulfate-induced colitis in mice

Exopolysaccharide from Bifidobacterium breve alleviate dextran sulfate sodium-induced colitis in mice via inhibiting oxidative stress and regulating intestinal flora

Bifidobacterium Longum, Lactobacillus Plantarum and Pediococcus Acidilactici Reversed ETEC-Inducing Intestinal Inflammation in Mice